San Diego, May 15th 2017 - Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted a ...
San Diego, May 15th 2017 - Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted a ...
Nerviano, Italy (March 15, San Diego, CA Trovagene, Inc. NASDAQ: TROV) - Trovagene, a precision medicine biotechnology company and Nerviano Medical Sciences, S.r.l., a leading oncology discovery organization, ...
Nerviano, Italy (March 15, San Diego, CA Trovagene, Inc. NASDAQ: TROV) - Trovagene, a precision medicine biotechnology company and Nerviano Medical Sciences, S.r.l., a leading oncology discovery organization, ...
5. Discovery Platforms
(Oncology (en))
Kinase Platform Kinases are one of the most important drug target classes in several therapeutic areas, and particularly in Oncology, with >30 drugs already approved for a wide variety of solid tumors ...
Milan, Italy 9th February 2017 SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that updated results from two ...
San Diego - Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that updated results from two Phase 1 trials of entrectinib—the company's investigational, ...
Nerviano, Italy 2nd December 2016 SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced data examining the combination ...
San Diego - Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced data examining the combination of entrectinib and trametinib in overcoming resistance ...
... in the Oncology R&D sector. During the event NMS researchers described the targeted anticancer effects obtained in preclinical models with an ADC obtained by combining the thienoindole NMS-P945 with ...
... in the Oncology R&D sector. During the event NMS researchers described the targeted anticancer effects obtained in preclinical models with an ADC obtained by combining the thienoindole NMS-P945 with ...
... drug conjugates (ADCs) against new targets in oncology and Nerviano Medical Sciences (Nerviano), a company of the NMS Group dedicated to the discovery and development of breakthrough treatments for cancer, ...
... drug conjugates (ADCs) against new targets in oncology and Nerviano Medical Sciences (Nerviano), a company of the NMS Group dedicated to the discovery and development of breakthrough treatments for cancer, ...
... antibody-based therapeutics with antibody drug conjugate (ADCs) and immuno-oncology approaches for the treatment of cancer. The company’s therapies are directed at targets selected from an exclusive cancer ...
... of innovative antibody-based therapeutics with antibody drug conjugate (ADCs) and immuno-oncology approaches for the treatment of cancer. The company’s therapies are directed at targets selected from an ...
...    Jean-Pierre Abastado, Ph.D., Director of the Oncology Innovation Therapeutic Pole at Servier, said: “We are very enthusiastic about the initiation of this study as S 81694 (NMS-P153) is a novel ...
... of Nerviano.   Jean-Pierre Abastado, Ph.D., Director of the Oncology Innovation Therapeutic Pole at Servier, said: “We are very enthusiastic about the initiation of this study as S 81694 (NMS-P153) ...
... escape traditional oncology therapies. Cancer stem cells are also responsible for relapses of this tumor, absolutely the most lethal ones. Thanks to its toxicological research, Accelera - of NMS Group ...
... escape traditional oncology therapies. Cancer stem cells are also responsible for relapses of this tumor, absolutely the most lethal ones. Thanks to its toxicological research, Accelera - of NMS Group ...
London, January 20, 2015 - Tiziana Life Sciences plc (“Tiziana”, “the Company”, AIM: TILS), the clinical stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, ...
Nerviano, October 28, 2014 – Nerviano Medical Sciences announces that results from a single-arm Phase II study of Milciclib in patients with thymic carcinoma and thymoma were disclosed in a poster discussion ...
Nerviano, September 29, 2014 - Nerviano Medical Sciences partner Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, presented interim results from the first-in-human ALKA-372-001 ...
August 4, 2014 - San Diego, CA, USA & Nerviano, Italy --(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, and Nerviano Medical Sciences, S.r.l., a ...
... and industrial research Nerviano Medical Sciences Group develops today.” About Cellectis Cellectis is a biopharmaceutical company focused on oncology. The company’s mission is to develop a novel generation ...
... in patients with advanced solid tumors with relevant molecular alterations will be disclosed at the 2014 American Society of Clinical Oncology (ASCO) annual meeting.   Presentation title: Phase ...
... results of Miciclib in patients with thymic carcinoma will be reported at the 2014 American Society of Clinical Oncology (ASCO) annual meeting. Presentation title: A phase II study of milciclib (PHA-848125AC) ...
... these articles at the following link: http://www.nervianoms.com/en/oncology-en/publications.html            ...
... and among the most important in Europe, in the field of research and development in oncology. NMS is already able to boast important cooperation or licensing agreements with pharmaceutical companies such ...
... in oncology. NMS is already able to boast important cooperation or licensing agreements with pharmaceutical and biotech companies such as Genentech (Roche), Pfizer, Novartis and Servier, as well as with ...
Nerviano - Italy and Suresnes – France, July 30th, 2013 —Nerviano Medical Sciences, the largest pharmaceutical R&D facility in Italy, one of the leading oncology-focused, integrated discovery and ...
Medicinal Chemistry and all of Oncology’s integrated chemical core technologies are set up to provide the synthetic chemistry output and medicinal chemistry competence for effectively advancing the drug ...
32. Cell bank and cell proliferation
(Capabilities (en))
The NMS Cell Bank (CB) manages and distributes controlled, high quality cell lines for all the laboratories in Nerviano in order to ensure the highest quality and reproducibility of the cellular experiments. ...
33. Cell assay technologies
(Capabilities (en))
The Unit develops and implements single-cell analytical approaches, including microscopy (bright field, fluorescence, confocal, time-lapse), flow cytometry, and high-content analysis. In particular, ...
34. Fragment based drug discovery
(Capabilities (en))
A multidisciplinary core team leverages on synergies between biophysical screening methods, structural and synthetic chemistry. The activities have an important role in assessing druggability of new targets, ...
35. Core services
(CLIOSS (en))
... to EVMPD via EV-Web Acknowledgment Management Clinical Data Management Data Management Plan Case Report Form, Design and Development (extensive library of Oncology specific modules available) ...
36. Partnerships
(CLIOSS (en))
Partnership with Lombardy Oncology Network (Rete Oncologica Lombarda) and Lombardy Hematology Network (Rete Ematologica Lombarda). Partnership with renowned European and US development sites: ...
37. Expertise
(CLIOSS (en))
... experience in oncology clinical development from cytotoxics to hormonals and targeted therapies: INDICATIONS Acute Leukemia Chronic Leukemia Multiple Myeloma Myelodisplastic Syndromes ...
38. Nerpharma
(Nerpharma (en))
... Group, operates in fact as a Contract Development and Manufacturing Organization (CDMO) and is characterized by a strong specialization in oncology, which guarantees the highest standards of quality and ...
... a full range of clinical developments services to Healthcare Players thanks to the scientific heritage in oncology derived from Nerviano’s research site and to its team of professionals with a wide experience ...
40. CLIOSS
(CLIOSS (en))
... today headed by NMS Group, CLIOSS has a particular specialization in clinical development in oncology and onco-hematology. Further details at Clioss website.      ...
41. Capabilities
(Oncology (en))
Our expanding discovery and development capabilities array includes classical and innovative approaches to drug discovery, fully integrated within the Oncology division.  ...
42. Purinome platform
(Technology Platforms (en))
The generation of novel chemotypes in support of our oncology research projects expanded in recent years from a canonical design of kinase targeted compound libraries to a broader interpretation of purinome ...
43. Kinase platform
(Technology Platforms (en))
Our Oncology unit has developed a methodological platform to discover small molecule kinase inhibitors, which we refer to as the ‘Kinase Platform’. A panel of over 90 cloned and expressed kinases is ...
44. Danusertib
(Pipeline (en))
... Inhibitor Danusertib in Patients With Advanced or Metastatic Solid Tumors, Journal of Clinical Oncology 2009,27:30(5094-5101) A phase I dose-escalation study of danusertib (PHA-739358) administered as ...
45. Nemorubicin
(Pipeline (en))
... (HCC): First step results, American Society of Clinical Oncology Annual Meeting 2009,May 31(Abs 4593) Sun Y,Yang J, Luo P, et al. Efficacy of Nemorubicin (MMDX) administered with iodinated oil via hepatic ...
46. NMS publications
(Science Corner (en))
... animal models for in vivo target identification and validation in oncology Texido G Methods Mol Biol (2013), (986), 281-305 View abstract on PubMed Antitumor efficacy on glioma models ...
47. Oncology seminars
(Science Corner (en))
We are glad to host external speakers to present their latest findings at our Oncology Seminars Series. Usual topics include themes related to the biology of cancer, chemical approaches, and in general ...
48. Meetings and congresses
(Science Corner (en))
... CA Web link September 8-12 40 Congress of the European Society of Medical Oncology Madrid , Spain Web link  ...
49. Pipeline
(Oncology (en))
... includes innovative driver oncogenes, cell cycle and DNA repair mechanisms, metabolic and immune-oncology pathways, as well as novel ADC payloads. Nerviano’s novel drug-linker technology of new DNA ...
To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.